News

Orchid Pharma Ltd share price gained 1.32% to Rs 1047.1. The Company`s net profit plunged by 89.61% to Rs 2.58 crore, while revenue from operations reduced 17.42% to Rs 304.17 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, rising 4.13%. It has inched up 0.05% over last one week and moving up by 10.53% in last one month while the market capitalization of Orchid Pharma Ltd has marginally improved by 4.23% and 175.63% in the same period respectively. Profit before tax (PBT) of Orchid Pharma Ltd stood at Rs 2.65 crore in Q2 FY26, tumbling by 138.46% year-on-year, and nosediving by 89.34% quarter-on-quarter. EBITDA came in at Rs 12 crore, tanking 170.67% YoY and plunging by 45.65% sequentially. Total expenses fell by 13.74% to Rs 301.12 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 206.42 crore, slightly declining by 1.63% YoY, while employee benefits expense was at Rs 28.04 crore, ticking higher by 1.52% YoY. For the TTM ended FY26, revenue from operations grew 12.52% to Rs 921.93 crore, while net profit grew slightly 0.74% to Rs 95.76 crore, compared to previous TTM. EBITDA soared by 8013% to Rs 89.71 crore, and PBT saw a minor gain of 3.93% to Rs 95.56 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 19.22 crore in FY26, as against Rs 125.99 crore in FY25. Orchid Pharma Ltd surged by 39.91% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 3.21% during the same period.

Orchid Pharma will hold a meeting of the Board of Directors of the Company on 1 August 2026.

Net profit of Orchid Pharma rose 6.68% to Rs 23.78 crore in the quarter ended March 2026 as against Rs 22.29 crore during the previous quarter ended March 2025. Sales rose 0.05% to Rs 237.61 crore in the quarter ended March 2026 as against Rs 237.48 crore during the previous quarter ended March 2025.For the full year,net profit declined 79.38% to Rs 20.55 crore in the year ended March 2026 as against Rs 99.66 crore during the previous year ended March 2025. Sales declined 12.00% to Rs 811.33 crore in the year ended March 2026 as against Rs 921.93 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales237.61237.48 0 811.33921.93 -12 OPM %11.3111.78 -5.0712.71 - PBDT31.1127.97 11 63.04130.11 -52 PBT22.2519.09 17 27.5995.56 -71 NP23.7822.29 7 20.5599.66 -79 Powered by Capital Market - Live News

Orchid Pharma will hold a meeting of the Board of Directors of the Company on 25 May 2026.

Net loss of Orchid Pharma reported to Rs 12.61 crore in the quarter ended December 2025 as against net profit of Rs 20.78 crore during the previous quarter ended December 2024. Sales declined 4.63% to Rs 207.27 crore in the quarter ended December 2025 as against Rs 217.34 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales207.27217.34 -5 OPM %0.7512.13 - PBDT3.9931.06 -87 PBT-5.0422.45 PL NP-12.6120.78 PL Powered by Capital Market - Live News